Strategic Investor Briefing · 2026
Pathological Examination Market. A USD 333 billion global diagnostics industry scaling to USD 773 billion by 2030, reshaping around AI, digital workflows, and personalised medicine.
2023 market value
Forecast CAGR
2030 forecast
$333.41B
12.8%
$772.79B
Established baseline
2024 → 2030 horizon
Addressable opportunity
Industry Ecosystem
A four-rail taxonomy type, service, application, end user delivers care across hospitals, clinics, and ambulatory surgical centers in 28 geographies, contested by 10 profiled competitors.
What this briefing covers
Traditional histology workstreams are being re-platformed — slide preparation to case signto case sign-out is going digital, interpretable, and AI-assisted.
01 Drivers
02 Segmentation
03 Competition
04 Regions
Chronic disease, geriatric, AI, and APAC capital flows.
Type, service, application, and enduser cuts.
10 profiled players, partnerships, and M&A moves.
North America anchored, APAC inflecting.
Source: Next Move Strategy Consulting — Pathological Examination Market Report (Base year 2023).
01 / 06
Drivers & Opportunities · 02
Four reinforcing forces accelerating pathology demand. 12.8%
Demand signal · 2024 → 2030
A 2.32× expansion in addressable spend.
01
Driver
Chronic disease burden
CAGR
02
Driver
Ageing population
Cardiovascular, oncology, lung disease, and type 2 diabetes drive the bulk of
Demographic ageing across North America, Europe, and developed Asia lifts
the bulk of pathology volume pulling forward routine diagnostic demand
age-related clinical-pathology volume and lengthens the routine screening
demand across developed and emerging systems.
tail.
Signal
Signal
US expected to record 2 million+ new cancer cases in 2024 about 5,500 diagnoses daily (ACS).
Japan has 36.23 million residents aged 65+ (WEF, 2023).
03
04
Driver
Digital workflows & AI
Driver
Asia-Pacific capital flow
Whole-slide imaging and AI-augmented interpretation compress
Surging PE activity, growing middle-class demand, and 3D-imaging adoption
turnaround, lift diagnostic accuracy, and extend specialist reach through
reshape the diagnostic landscape across China, India, Japan, and Southeast
remote case review.
Asia.
Signal
Signal
Roche × PathAI, Feb 2024 AI for companion-diagnostic interpretation.
India saw USD 4 billion healthcare inflows in 2023; PE up 9–10% YoY.
Emerging tech
3D imaging & expansion microscopy
Reshape cytology at the sub-cellular level — opening capacity for earlyearly-stage oncology panels traditional slides cannot resolve.
Drivers anchored to NextMSC primary research; signals cross-verified against ACS, WEF 2023, and IBEF 2023–24.
02 / 06
Segmentation & Scope · 03
The market is read along four structural cuts. Coverage
Type, service, application, and end-user together define where the 12.8% trajectory lands and where investors should anchor their thesis work.
28 countries
10 players profiled Digital pathology
Cut
Conventional pathology
By type
Glass-slide workflows and reagent-based histology the legacy backbone of case sign-out.
Whole-slide imaging + AI interpretation; fastest-migrating rail migrating rail share rising though 2030.
2 segments
Cut 02
By service Five disciplines that make up any any pathology lab.
01
02
03
04
05
Surgical
Anatomic
Cytopathology
Molecular
Clinical
Intraoperative and resected-tissue workflows.
Tissue-based diagnostic practice.
Cell-level disease detection.
Genomic and biomarker testing.
Blood, urine, fluidfluid-based labs.
Cut 03
Cut 04
By application
By end user
Digestive organs
Hospitals
GI biopsies, hepatic panels, pancreatic resections.
Largest procurement channel; integrated AP/CP labs dominate share.
Blood
Hematologic malignancies, coagulation, transfusion medicine.
Clinics
Outpatient cytology and biopsy referral volume. Others
Dermatopathology, neuropathology, gynaecologic cytology.
Ambulatory surgical centers
Fastest-growing site of service for surgical pathology.
Cuts per NextMSC Pathological Examination Market segmentation framework.
03 / 06
Competitive Landscape · 04
Ten profiled players consolidating around AI.
10 players
Big-IVD leaders sit alongside specialist and regional labs M&A and AI partnerships are reshaping the rail between conventional histology and digital interpretation.
3 named moves, 2021–24
Positioning matrix
Strategic moves
Tech posture × Geographic scope
Three 2021–24 plays
AI-Native · Regional
Feb 2024
AI-Native · Global
Roche × PathAI 3DHISTECH
AI algorithms paired with Roche's companion-
Roche
diagnostic franchise. Quest Diagnostics
NeoGenomics Labs
Mar 2022
Abbott Pathology
Roche × BMS Digital pathology for clinical-trial assays — Sonic Healthcare
BD and Company
Diagnostic Pathology Services
VENTANA PD-L1 and CD8.
Merck KGaA
Healio
Dec 2021 Conventional · Global
Conventional · Regional
Sonic × ProPath Acquired a US anatomical-pathology group to
Indicative placement — chip position reflects current portfolio mix, not revenue weight; axes are illustrative.
group to fuse AP with clinical-lab services.
Ten profiled players · full roster
Roche
Abbott Pathology
Global IVD leader, AI-led
Diversified diagnostics
Merck KGaA
NeoGenomics Labs
3DHISTECH
Diag. Pathology Svcs.
Oncology-focused specialist
Digital-pathology hardware
US regional pathology
Life-science supplier, reagents
Quest Diagnostics US reference-laboratory scale
Sonic Healthcare AP + clinical-lab integration
BD & Co. Global diagnostics platform
Healio Publishing & content network
Investor read
What to watch
Consolidation is shifting share toward players that can fuse AI interpretation, clinical-lab scale, and reimbursement muscle — conventional-glass incumbents without a digital path will see share drift through 2030, while AI-native specialists and M&A-active mid-caps shape the next rail of the market.
Stratgic moves anchored to publicly announced partnerships and acquisitions; company roster per NextMSC profiling.
04 / 06
Regional Outlook · 05
North America anchors the present APAC the future. Established diagnostics markets carry most 2023 share; Asia-Pacific accelerates fastest as demographics, PE inflows, and digital capacity scale through 2030.
Coverage
28 countries
Region 02 · Mature
Region 01 · Largest share
Europe
North America
Mature infrastructure across the UK, Germany, France, Italy, Spain and
2M+
and Nordics. Demand tracks demographic ageing and the rollout of of companion-diagnostic reimbursement.
new US cancer cases projected for 2024 (ACS) about 5,500 diagnoses daily.
Region 03 · Fastest growth
Asia-Pacific Established reference labs (Jackson Memorial, Advent Health Orlando) and Orlando) and a deep reimbursement framework keep the US as the the cornerstone of the global pathology pipeline through 2030.
36.23M
USD 4B
Japan residents aged 65+ (WEF, 2023).
India healthcare inflows 2023 — PE up 9–10% YoY.
Region 04 · Emerging
Rest of World
China, India, Japan, South Korea, Australia, Indonesia, Singapore, Taiwan, Taiwan, Thailand anchor the region — 20+ PE deals worth USD 3.8 billion closed
Latin America, Middle East and Africa anchor opportunity in public-hospital
billion closed into hospitals, devices, and diagnostics in 2023.
public-hospital modernisation, mobile labs, and reference-lab partnerships
partnerships with global IVD players.
Where the curve bends
Capital, age, and digital capacity together define the 2030 mix. Anchor
Inflect
Watch
North America — scale, reimbursement, routine screening.
APAC — demographics and PE capital.
Europe + RoW — gradual modernisation.
Triangulate country-level reimbursement, geriatric dependency ratio, and digital-pathology readiness when sizing exposure.
Regional signals cross-verified against ACS, WEF 2023, and PE deal trackers; country figures from NextMSC report.
05 / 06
Next steps · 06
Thank you. We welcome a continued conversation with investors, internal strategy teams, and B2B decision-makers on the global pathology opportunity.
Website
nextmsc.com Official research portal full reports, country-level cuts, and analyst access.
Phone
+1 857 758 5017 Direct line to our research desk
info@nextmsc.com Direct inquiries replies within one business day.
CLICK HERE
Take the next step
Receive the complete Pathological Examination Market report — segmentation tables, country-level forecasts, and 80 analyst-hours of free customization.
Full report
CLICK HERE
→
nextmsc.com/report/pathological-examination-market
Follow Next Move
Stay close to the diagnostic frontier.
in
f
play
x
ig
YouTube
linkedin.com/company/ next-move-strategy-consulting
facebook.com/ Next-Move-StrategyConsulting
youtube.com/channel/ UCJuVRxfBoDsog7BgDE4uPQ
twitter.com/ nextmsc
instagram.com/ nextmsc
© Next Move Strategy Consulting Pathological Examination Market briefing.
06 / 06